Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. It is involved in developing Linac Image Guided Hadron technology, a proton therapy system for treating cancer. The company is also involved in the management of a healthcare related property. It operates in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
SymbolLON:AVO
CUSIPN/A
Phone+44-20-36178728
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.18%
Return on Assets-35.03%
Miscellaneous
EmployeesN/A
Outstanding Shares80,940,000
Market Cap£41.31
Advanced Oncotherapy (LON:AVO) Frequently Asked Questions
What is Advanced Oncotherapy's stock symbol?
Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."
What is the consensus analysts' recommendation for Advanced Oncotherapy?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Advanced Oncotherapy's key competitors?
Some companies that are related to Advanced Oncotherapy include Ellex Medical Lasers (ELXMF), Creo Medical Group (CREO), Hamilton Thorne (HTL), Kromek Group (KMK), Electromed (ELMD), Universal Biosensors (UBI), Protech Home Medical (PHM), MRI Interventions (MRIC), Surgical Innovations Group (SUN), Neuroone Medical Technologies (NMTC), PetVivo (PETV), Avacta Group (AVCT), Myomo (MYO), GI Dynamics (GID) and Airware Labs (AIRW).
Who are Advanced Oncotherapy's key executives?
Advanced Oncotherapy's management team includes the folowing people:
- Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 75)
- Mr. Nicolas Serandour, CEO & Exec. Director
- Dr. Sanjeev Pandya, Exec. VP for Global Bus. Devel. and Exec. Director
- Mr. Ed Lee, COO & Sr. VP of Operations
- Mr. Graham Pughe, Sr. VP of Accounting & IT
Has Advanced Oncotherapy been receiving favorable news coverage?
Media stories about AVO stock have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advanced Oncotherapy earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media stories about the company an impact score of 45.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Advanced Oncotherapy?
Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Advanced Oncotherapy's stock price today?
One share of AVO stock can currently be purchased for approximately GBX 52.50.
How big of a company is Advanced Oncotherapy?
Advanced Oncotherapy has a market capitalization of £41.31 million.
How can I contact Advanced Oncotherapy?
Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.
MarketBeat Community Rating for Advanced Oncotherapy (LON AVO)
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
